{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:28Z","timestamp":1793390728789,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMFHR115039"],"award-info":[{"award-number":["CMFHR115039"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Yang Ming Chiao Tung University","id":[{"id":"https:\/\/ror.org\/00se2k293","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08134-y","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:27:55Z","timestamp":1783751275000},"page":"2451-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0552-569X","authenticated-orcid":false,"given":"Hsin-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6265-5155","authenticated-orcid":false,"given":"Chun-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"8134_CR1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jama.2024.1416","volume":"331","author":"CS Col\u00f3n-Emeric","year":"2024","unstructured":"Col\u00f3n-Emeric CS, Mcdermott CL, Lee DS, Berry SD (2024) Risk assessment and prevention of falls in older community-dwelling adults: a review. JAMA 331:1397\u20131406. https:\/\/doi.org\/10.1001\/jama.2024.1416","journal-title":"JAMA"},{"key":"8134_CR2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/aje\/kwp266","volume":"170","author":"SE Bentler","year":"2009","unstructured":"Bentler SE, Liu L, Obrizan M et al (2009) The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol 170:1290\u20131299. https:\/\/doi.org\/10.1093\/aje\/kwp266","journal-title":"Am J Epidemiol"},{"key":"8134_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2105\/ajph.82.7.1020","volume":"82","author":"BH Alexander","year":"1992","unstructured":"Alexander BH, Rivara FP, Wolf ME (1992) The cost and frequency of hospitalization for fall-related injuries in older adults. Am J Public Health 82:1020\u20131023. https:\/\/doi.org\/10.2105\/ajph.82.7.1020","journal-title":"Am J Public Health"},{"key":"8134_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024067","volume":"9","author":"H Wang","year":"2019","unstructured":"Wang H, Ba Y, Xing Q, Du JL (2019) Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 9:e024067. https:\/\/doi.org\/10.1136\/bmjopen-2018-024067","journal-title":"BMJ Open"},{"key":"8134_CR5","doi-asserted-by":"publisher","unstructured":"Koster A, Schaap LA (2015) The effect of type 2 diabetes on body composition of older adults. Clin Geriatr Med 31:41\u20139, vii-viii. https:\/\/doi.org\/10.1016\/j.cger.2014.08.020","DOI":"10.1016\/j.cger.2014.08.020"},{"key":"8134_CR6","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/archinte.165.14.1612","volume":"165","author":"ES Strotmeyer","year":"2005","unstructured":"Strotmeyer ES, Cauley JA, Schwartz AV et al (2005) Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612\u20131617. https:\/\/doi.org\/10.1001\/archinte.165.14.1612","journal-title":"Arch Intern Med"},{"key":"8134_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jbiomech.2017.06.027","volume":"60","author":"J Cie\u015bli\u0144ska-\u015awider","year":"2017","unstructured":"Cie\u015bli\u0144ska-\u015awider J, Furmanek MP, B\u0142aszczyk JW (2017) The influence of adipose tissue location on postural control. J Biomech 60:162\u2013169. https:\/\/doi.org\/10.1016\/j.jbiomech.2017.06.027","journal-title":"J Biomech"},{"key":"8134_CR8","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M (2023) Obesity management in adults: a review. JAMA 330:2000\u20132015. https:\/\/doi.org\/10.1001\/jama.2023.19897","journal-title":"JAMA"},{"issue":"Suppl 1","key":"8134_CR9","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.2337\/dc26-S004","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S61\u2013S88. https:\/\/doi.org\/10.2337\/dc26-S004","journal-title":"Diabetes Care"},{"key":"8134_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158214","volume":"25","author":"Z Szekeres","year":"2024","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E (2024) Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review. Int J Mol Sci 25:8214. https:\/\/doi.org\/10.3390\/ijms25158214","journal-title":"Int J Mol Sci"},{"key":"8134_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12777","volume":"81","author":"G Luo","year":"2016","unstructured":"Luo G, Liu H, Lu H (2016) Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol 81:78\u201388. https:\/\/doi.org\/10.1111\/bcp.12777","journal-title":"Br J Clin Pharmacol"},{"key":"8134_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"Hansen MS, W\u00f6lfel EM, Jeromdesella S et al (2024) Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 72:102624. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102624","journal-title":"EClinicalMedicine"},{"key":"8134_CR13","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.2147\/dddt.S531778","volume":"19","author":"Q Ren","year":"2025","unstructured":"Ren Q, Zhi L, Liu H (2025) Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study. Drug Des Devel Ther 19:5645\u20135652. https:\/\/doi.org\/10.2147\/dddt.S531778","journal-title":"Drug Des Devel Ther"},{"key":"8134_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/dom.12843","volume":"19","author":"JH Driessen","year":"2017","unstructured":"Driessen JH, Van Den Bergh JP, Van Onzenoort HA, Henry RM, Leufkens HG, De Vries F (2017) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab 19:421\u2013428. https:\/\/doi.org\/10.1111\/dom.12843","journal-title":"Diabetes Obes Metab"},{"key":"8134_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bone.2016.11.026","volume":"95","author":"J Starup-Linde","year":"2017","unstructured":"Starup-Linde J, Gregersen S, Frost M, Vestergaard P (2017) Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes. Bone 95:136\u2013142. https:\/\/doi.org\/10.1016\/j.bone.2016.11.026","journal-title":"Bone"},{"key":"8134_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.825417","volume":"13","author":"S Chai","year":"2022","unstructured":"Chai S, Liu F, Yang Z et al (2022) Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks. Front Pharmacol 13:825417. https:\/\/doi.org\/10.3389\/fphar.2022.825417","journal-title":"Front Pharmacol"},{"key":"8134_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3168","volume":"35","author":"L Cheng","year":"2019","unstructured":"Cheng L, Hu Y, Li YY et al (2019) Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 35:e3168. https:\/\/doi.org\/10.1002\/dmrr.3168","journal-title":"Diabetes Metab Res Rev"},{"key":"8134_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117338","volume":"192","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen G, Wang W, Yang D, Zhu D, Jing Y (2025) Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials. Bone 192:117338. https:\/\/doi.org\/10.1016\/j.bone.2024.117338","journal-title":"Bone"},{"key":"8134_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamasurg.2025.5372","volume":"161","author":"WT Khor","year":"2026","unstructured":"Khor WT, Chi KY, Lin HM, Chang Y (2026) Glucagon-like peptide 1 receptor agonist use and vertebral fracture risk in type 2 diabetes. JAMA Surg 161:197\u2013199. https:\/\/doi.org\/10.1001\/jamasurg.2025.5372","journal-title":"JAMA Surg"},{"key":"8134_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121655","volume":"17","author":"F Lv","year":"2024","unstructured":"Lv F, Cai X, Lin C, Yang W, Ji L (2024) Effects of Semaglutide and Tirzepatide on bone metabolism in type 2 diabetic mice. Pharmaceuticals (Basel) 17:1655. https:\/\/doi.org\/10.3390\/ph17121655","journal-title":"Pharmaceuticals (Basel)"},{"key":"8134_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112924","volume":"229","author":"D Pantazopoulos","year":"2025","unstructured":"Pantazopoulos D, Gouveri E, Papazoglou D, Papanas N (2025) GLP-1 receptor agonists and sarcopenia: weight loss at a cost? A brief narrative review. Diabetes Res Clin Pract 229:112924. https:\/\/doi.org\/10.1016\/j.diabres.2025.112924","journal-title":"Diabetes Res Clin Pract"},{"key":"8134_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag052","author":"Y Liu","year":"2026","unstructured":"Liu Y, Walzer D, Schmitz S et al (2026) Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgag052","journal-title":"J Clin Endocrinol Metab"},{"key":"8134_CR23","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1001\/jama.2011.715","volume":"305","author":"AV Schwartz","year":"2011","unstructured":"Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184\u20132192. https:\/\/doi.org\/10.1001\/jama.2011.715","journal-title":"JAMA"},{"key":"8134_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"Hofbauer LC, Busse B, Eastell R et al (2022) Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 10:207\u2013220. https:\/\/doi.org\/10.1016\/s2213-8587(21)00347-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8134_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15062284","volume":"15","author":"H Kang","year":"2026","unstructured":"Kang H, Choi M, Roh Y, Yoon Y, Hwang J (2026) Visceral adiposity, rather than reduced appendicular lean mass, characterizes elderly hip fracture patients with type 2 diabetes: a cross-sectional DXA analysis. J Clin Med 15:2284. https:\/\/doi.org\/10.3390\/jcm15062284","journal-title":"J Clin Med"},{"key":"8134_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.exger.2016.12.007","volume":"94","author":"K Martyniak","year":"2017","unstructured":"Martyniak K, Masternak MM (2017) Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation. Exp Gerontol 94:59\u201363. https:\/\/doi.org\/10.1016\/j.exger.2016.12.007","journal-title":"Exp Gerontol"},{"key":"8134_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116880","volume":"176","author":"B Wang","year":"2023","unstructured":"Wang B, Vashishth D (2023) Advanced glycation and glycoxidation end products in bone. Bone 176:116880. https:\/\/doi.org\/10.1016\/j.bone.2023.116880","journal-title":"Bone"},{"key":"8134_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiomech.2024.111962","volume":"164","author":"J Ahn","year":"2024","unstructured":"Ahn J, Ban R, Simpkins C, Yang F (2024) Android obesity could be associated with a higher fall risk than gynoid obesity following a standing-slip: a simulation-based biomechanical analysis. J Biomech 164:111962. https:\/\/doi.org\/10.1016\/j.jbiomech.2024.111962","journal-title":"J Biomech"},{"key":"8134_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U et al (2022) Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 10:193\u2013206. https:\/\/doi.org\/10.1016\/s2213-8587(22)00008-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8134_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1386542","volume":"15","author":"B Rodr\u00edguez Jim\u00e9nez","year":"2024","unstructured":"Rodr\u00edguez Jim\u00e9nez B, Rodr\u00edguez De Vera G\u00f3mez P, Belmonte Lomas S et al (2024) Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Front Endocrinol (Lausanne) 15:1386542. https:\/\/doi.org\/10.3389\/fendo.2024.1386542","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8134_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","volume":"25","author":"A Bikou","year":"2024","unstructured":"Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother 25:611\u2013619. https:\/\/doi.org\/10.1080\/14656566.2024.2343092","journal-title":"Expert Opin Pharmacother"},{"key":"8134_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1 (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10:393\u2013406. https:\/\/doi.org\/10.1016\/s2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8134_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise T, Devries JH, Urva S et al (2023) Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 46:998\u20131004. https:\/\/doi.org\/10.2337\/dc22-1710","journal-title":"Diabetes Care"},{"key":"8134_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020224","volume":"58","author":"I Daniilopoulou","year":"2022","unstructured":"Daniilopoulou I, Vlachou E, Lambrou GI et al (2022) The impact of GLP1 agonists on bone metabolism: a systematic review. Medicina (Kaunas) 58:224. https:\/\/doi.org\/10.3390\/medicina58020224","journal-title":"Medicina (Kaunas)"},{"key":"8134_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.697442","volume":"12","author":"B Xie","year":"2021","unstructured":"Xie B, Chen S, Xu Y et al (2021) The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment. Front Pharmacol 12:697442. https:\/\/doi.org\/10.3389\/fphar.2021.697442","journal-title":"Front Pharmacol"},{"key":"8134_CR36","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jbmr.1898","volume":"28","author":"X Ma","year":"2013","unstructured":"Ma X, Meng J, Jia M et al (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 28:1641\u20131652. https:\/\/doi.org\/10.1002\/jbmr.1898","journal-title":"J Bone Miner Res"},{"key":"8134_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1539411","volume":"16","author":"Y Tian","year":"2025","unstructured":"Tian Y, Liu H, Bao X, Li Y (2025) Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt\/LRP5\/\u03b2-catenin signaling pathway. Front Pharmacol 16:1539411. https:\/\/doi.org\/10.3389\/fphar.2025.1539411","journal-title":"Front Pharmacol"},{"key":"8134_CR38","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/eurheartj\/ehaf690","volume":"47","author":"B Park","year":"2025","unstructured":"Park B, Dennis F, He AZ et al (2025) Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. Eur Heart J 47:1171\u20131182. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf690","journal-title":"Eur Heart J"},{"key":"8134_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac004","author":"MS Hansen","year":"2023","unstructured":"Hansen MS, S\u00f8e K, Christensen LL et al (2023) GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur J Endocrinol. https:\/\/doi.org\/10.1093\/ejendo\/lvac004","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 4","key":"8134_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL (2024) Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 26(Suppl 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728","journal-title":"Diabetes Obes Metab"},{"key":"8134_CR41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89020","volume":"17","author":"RA Hidalgo Ramos","year":"2025","unstructured":"Hidalgo Ramos RA, Hong I, Ortiz M, Secades D, Dufner Krieger S, Ramos Stanziola L (2025) Effects of tirzepatide on skeletal muscle mass in adults: a systematic review. Cureus 17:e89020. https:\/\/doi.org\/10.7759\/cureus.89020","journal-title":"Cureus"},{"key":"8134_CR42","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","volume":"86","author":"MM Kittleson","year":"2025","unstructured":"Kittleson MM, Benjamin EJ, Blumer V et al (2025) 2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology. J Am Coll Cardiol 86:1953\u20131975. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.008","journal-title":"J Am Coll Cardiol"},{"key":"8134_CR43","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/s0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K et al (2025) Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405:1580\u20131593. https:\/\/doi.org\/10.1016\/s0140-6736(25)00509-4","journal-title":"Lancet"},{"key":"8134_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112083","volume":"222","author":"JY Wu","year":"2025","unstructured":"Wu JY, Tu WL, Yu T, Liao KM, Lin YM (2025) Tirzepatide and major adverse limb events: insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract 222:112083. https:\/\/doi.org\/10.1016\/j.diabres.2025.112083","journal-title":"Diabetes Res Clin Pract"},{"key":"8134_CR45","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S et al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 391:1573\u20131583. https:\/\/doi.org\/10.1056\/NEJMoa2403664","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08134-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08134-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08134-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:02:45Z","timestamp":1793048565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08134-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8134"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08134-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hsin-Yu Chen, Jheng-Yan Wu, Yi-Hsin Chu, Tse-Wei Chen and Chun-Feng Huang declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}